BioLineRx Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	12.74	28.94	4.8	-	-	-
Revenue Growth (YoY)	-42.09%	502.92%	-	-	-	-
Cost of Revenue	6.28	9.26	3.69	-	-	-
Gross Profit	6.46	19.68	1.11	-	-	-
Selling, General & Admin	8.99	29.68	31.58	11.53	5.31	4.75
Research & Development	7.53	9.15	12.52	17.63	19.47	18.17
Operating Expenses	16.53	38.83	44.1	29.16	24.78	22.93
Operating Income	-10.07	-19.15	-42.99	-29.16	-24.78	-22.93
Interest Expense	-5.44	-9.07	-2.14	-1.79	-0.98	-1.47
Interest & Investment Income	1.45	1.82	2.01	0.69	0.28	0.24
Currency Exchange Gain (Loss)	0.05	0.05	0.06	-0.35	0.28	-0.14
Other Non Operating Income (Expenses)	12.29	18.39	-10.84	5.64	-1.85	-5.72
EBT Excluding Unusual Items	-1.72	-7.97	-53.91	-24.95	-27.05	-30.02
Asset Writedown	-1.26	-1.26	-6.7	-	-	-
Pretax Income	-2.98	-9.22	-60.61	-24.95	-27.05	-30.02
Net Income	-2.98	-9.22	-60.61	-24.95	-27.05	-30.02
Net Income to Common	-2.98	-9.22	-60.61	-24.95	-27.05	-30.02
Shares Outstanding (Basic)	2,127	1,198	963	774	663	253
Shares Outstanding (Diluted)	2,127	1,198	963	774	663	253
Shares Change (YoY)	86.44%	24.37%	24.47%	16.75%	162.19%	72.70%
EPS (Basic)	-0.00	-0.01	-0.06	-0.03	-0.04	-0.12
EPS (Diluted)	-0.00	-0.01	-0.06	-0.03	-0.04	-0.12
Free Cash Flow	-13.48	-43.93	-22.72	-26.37	-23.67	-23.21
Free Cash Flow Per Share	-0.01	-0.04	-0.02	-0.03	-0.04	-0.09
Gross Margin	50.70%	67.99%	23.08%	-	-	-
Operating Margin	-79.08%	-66.18%	-895.65%	-	-	-
Profit Margin	-23.38%	-31.86%	-1262.79%	-	-	-
Free Cash Flow Margin	-105.83%	-151.78%	-473.42%	-	-	-
EBITDA	-8.37	-15.7	-41.67	-28.5	-24.07	-21.99
EBITDA Margin	-65.73%	-54.25%	-	-	-	-
D&A For EBITDA	1.7	3.45	1.33	0.65	0.7	0.93
EBIT	-10.07	-19.15	-42.99	-29.16	-24.78	-22.93
EBIT Margin	-79.08%	-66.18%	-	-	-	-
Revenue as Reported	12.74	28.94	4.8	-	-	-

Updated Nov 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q